GBT’s Kirlian Research Update
Implements Advanced AI Big Data Methods. Researching Correlation of Huge Data Results with Health-Related Information
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- GBT Technologies, Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”), announced that GBT Tokenize (“GBT/Tokenize) is now implementing advanced AI big data analytics methods for Kirilian research results, to find potential correlation with health information.
The Kirlian Electrophotography research techniques produced viable results which the company is now investigating a possibility of potential correlation with health-related data. The result of the Kirlian imaging research includes vast amounts of data with a high complexity, one which requires an intelligent analytics method, such as advanced big data algorithms.
The first stage will be a pattern of identification, including indexing and the creation of data sets. The second stage will focus on rapid data classification and group content identification, including preliminary data insights. Based on this analysis the system will dispose redundant and non-relevant data, concluding a viable, possible correlation pointer. These pointers will go through another stage of consistency and occurrence analysis to reach a high percentage of possible correlation. The AI engine main task will be sifting through Kirlian image huge data, analyzing it, and then cross-reference it with health-related data to match a symptoms or conditions possibility. Machine learning algorithms will be accomplishing this enormous task providing insight for Kirilian images complex data.
The Kirlian techniques potentially aim for inclusion within its qTerm device - , and are based on the phenomenon known as electrical coronal discharge. GBT's research is focused on the investigation of Kirlian images with the use of machine learning technology to possibly detect early disease or health conditions symptoms.
“AI big data processing is a method to analyze massive amount of information to reveal valuable insights for that particular data, where potentially traditional data processing algorithm can’t manage. As we achieved viable, experimental results with our Kirilian Research, we are now recruiting our AI engine, and using its powerful, robust data processing and analytics capabilities, researching to find correlations to heath information, if any. Our AI technology we will be used for big data processing to detect anomalies within Kirilian images. We’ll look for unusual occurrences, unique patterns, and will create data graphs and categories. The system will define appropriate data ranges and boundaries. Anything outside of that range will be flagged as an anomaly that needs to be further investigated. Based on detected information the system will attempt to correlate health data with imaging findings. Finally, the system, if and once developed, will suggest a probability of a predicted future outcome according to found repetitive patterns. Using big data AI technology, we'll evaluate a possible implementation of this technology within our future qTerm releases to enable and further health related advisory systems. We strongly believe that this research has the potential to offer extraordinary vital health related information and implementing our AI big data techniques will be a major factor for its success.” Said Danny Rittman the Company’s CTO.
There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this system, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.
About Us
GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) () is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact:
Dr. Danny Rittman, CTO
